Nov 12, 2021 / 05:00PM GMT
Operator
Good day, and thank you for standing by. Welcome to the Nektar Therapeutics SITC conference call.
(Operator Instructions)
Please be advised that today's conference may be recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Vivian Wu from the IR team.
Vivian Wu -
Thank you, Crystal. Good afternoon, everyone, and thank you for joining us on today's analyst call to review data presented for Nektar's immuno-oncology pipeline at the 2021 Society of Immunotherapy for Cancer meeting.
Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's drug candidate, NKTR-255 and other potential drug candidates. Clinical trial results, the timing of the startup and plans for ongoing planned clinical trials with partners, the therapeutic potential of our drug candidates, the timing and outcome of regulatory decisions and future availability of clinical trial data. Because these statements relate to the future, they are subject to inherent uncertainties and
Nektar Therapeutics Investor and Analyst Call at SITC Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers